Irinotecan Kabi

Irinotecan, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancers, particularly metastatic disease, and is administered under the supervision of oncology specialists.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU manufacturing standards and providing reliable global distribution. All batches meet stringent regulatory requirements and are shipped with appropriate temperature control.

Irinotecan Kabi is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

- Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. - Colorectal cancer (adjuvant setting): reduces recurrence risk after surgical resection. - Refractory colorectal cancer: provides a therapeutic option after failure of first‑line therapies.

Irinotecan Kabi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: often delayed and may be severe. - Nausea and vomiting. - Neutropenia. - Fatigue.

Serious or Rare Side Effects: - Febrile neutropenia. - Life‑threatening diarrhea or intestinal perforation. - Severe allergic reactions (anaphylaxis).

Before initiating therapy, clinicians should observe several safety measures.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check enzymes before and during therapy. - Ensure adequate hydration: reduce risk of severe diarrhea. - Adjust dose in hepatic impairment: reduce dosage per clinical guidelines. - Avoid concurrent strong CYP3A4 inhibitors: may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several drug classes; awareness helps avoid harmful outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of neutropenia and diarrhea. - Concurrent myelosuppressive chemotherapy: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Antidiarrheal agents (e.g., loperamide) when used prophylactically: may mask symptoms.